全球未来医药健康产业孵化平台发布

Core Insights - The China Cell and Gene Therapy Conference (CSGCT) was held on September 12-13, marking the establishment of the China Cell and Gene Therapy Alliance and the launch of a global pharmaceutical health industry incubation platform [1] Industry Overview - Beijing has ranked first in the number of approved medical device products in the past three years [1] - The pharmaceutical health industry in Beijing is projected to reach a scale of 1.06 trillion yuan in 2024, representing a year-on-year growth of 8.7%, making it the first city in China to surpass one trillion yuan in this sector [1] Regional Development - Haidian District has developed into a "talent hub" where innovative research and clinical resources converge, hosting companies focused on cell and gene therapy drug development, such as Baituo Biotechnology, Yimiao Shenzhou, InnoVekang, and NuoSilande [1] - The district aims to promote the transition of China's CGT industry from "catching up" to "leading" through open policies, data, space, and mechanisms in collaboration with various sectors [1] Conference Significance - The CSGCT is recognized as one of the most influential international conferences in the field of cell and gene therapy in China, attracting key stakeholders including policymakers, scientists, clinicians, entrepreneurs, and investors for in-depth exchanges and collaboration [1]